AI assistant
TISSUE REGENIX GROUP PLC AGM Information 2021
7973_agm-r_2021-06-03_765103b6-dd53-48cf-8027-ba3313638d7f.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 7644A
Tissue Regenix Group PLC
03 June 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Result of AGM
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that at the AGM held earlier today, all resolutions were duly passed.
The results of the poll are set out below:
| Resolution | In favour | % | Against | % | Withheld | |
| 1 | Ordinary | 3,399,235,541 | 100 | 0 | 0 | 546,855 |
| 2 | Ordinary | 3,399,212,980 | 99.99 | 76,421 | 0.01 | 569,416 |
| 3 | Ordinary | 3,399,212,980 | 99.99 | 76,421 | 0.01 | 569,416 |
| 4 | Ordinary | 3,399,656,835 | 99.99 | 16,274 | 0.01 | 125,561 |
| 5 | Ordinary | 3,399,656,835 | 99.99 | 74,846 | 0.01 | 125,561 |
| 6 | Ordinary | 3,399,656,835 | 99.99 | 16,274 | 0.01 | 125,561 |
| 7 | Ordinary | 3,399,656,835 | 99.99 | 17,849 | 0.01 | 125,561 |
| 8 | Ordinary | 3,399,338,541 | 99.99 | 194,449 | 0.01 | 443,855 |
| 9 | Ordinary | 3,399,338,541 | 99.99 | 17,849 | 0.01 | 443,855 |
| 10 | Ordinary | 3,397,632,396 | 99.90 | 3,420,838 | 0.10 | 2,150,000 |
| 11 | Special | 3,397,632,396 | 99.31 | 23,283,587 | 0.69 | 2,150,000 |
| 12 | Special | 3,399,782,396 | 99.88 | 4,162,711 | 0.12 | 0 |
NB: Percentage of Votes cast excludes Withheld votes
The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 28 April 2021.
For more information:
| Tissue Regenix Group plc David Cocke, Chief Financial Officer |
www.tissueregenix.com Via Walbrook PR |
| Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price |
Tel: +44(0)20 7710 7600 |
| Walbrook PR Ltd Alice Woodings / Paul McManus |
Tel: +44 (0)20 7933 8780 [email protected] |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSSDFEDEFSEDM